Belimumab
Pharmaceutical drug
Belimumab, sold under the brand name Benlysta, is a human monoclonal antibody that inhibits B-cell activating factor (BAFF), also known as B-lymphocyte stimulator (BLyS). It is approved in the United States and Canada, and the European Union to treat systemic lupus erythematosus and lupus nephritis.
Nº Q1996249 ★
Common · Knowledge
Belimumab
Pharmaceutical drug
Belimumab, sold under the brand name Benlysta, is a human monoclonal antibody that inhibits B-cell activating factor (BAFF), also known as B-lymphocyte stimulator (BLyS). It is approved in the United States and Canada, and the European Union to treat systemic lupus erythematosus and lupus nephritis.
From Wikipedia
Belimumab, sold under the brand name Benlysta, is a human monoclonal antibody that inhibits B-cell activating factor (BAFF), also known as B-lymphocyte stimulator (BLyS). It is approved in the United States and Canada, and the European Union to treat systemic lupus erythematosus and lupus nephritis. The most common side effects include bacterial infections, such as bronchitis (infection in the lungs) and infection of the urinary tract (structures that produce or carry urine), diarrhea and nausea (feeling sick).
Text: Wikipédia, CC BY-SA 4.0. · Image: Fvasconcellos (talk · contribs) (Public domain) ·
Related cards
-
B
Blinatumomab
Pharmaceutical drug
Nº Q410189 ★
Not listed
-
Adalimumab
Pharmaceutical drug
Nº Q348260 ★★★
Not listed
-
Baricitinib
Chemical compound
Nº Q4860707 ★
Not listed
-
Ofatumumab
Chemical compound
Nº Q410656 ★
Not listed
-
P
Polatuzumab vedotin
Chemical compound
Nº Q19946115 ★
Not listed
-
B
Brentuximab vedotin
Pharmaceutical drug
Nº Q422324 ★
Not listed